<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.0 20040730//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties manuscript?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Metab</journal-id><journal-title>Cell metabolism</journal-title><issn pub-type="ppub">1550-4131</issn></journal-meta><article-meta><article-id pub-id-type="pmid">17011503</article-id><article-id pub-id-type="doi">10.1016/j.cmet.2006.09.003</article-id><article-id pub-id-type="manuscript">ukpmcpa197</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Non-DNA binding, dominant-negative, human PPAR&#x003b3; mutations cause lipodystrophic insulin resistance</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Agostini</surname><given-names>Maura</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="author-notes" rid="FN1">12</xref></contrib><contrib contrib-type="author"><name><surname>Schoenmakers</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="author-notes" rid="FN1">12</xref></contrib><contrib contrib-type="author"><name><surname>Mitchell</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Szatmari</surname><given-names>Istvan</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Savage</surname><given-names>David</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Aaron</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rajanayagam</surname><given-names>Odelia</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Semple</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Luan</surname><given-names>Jian&#x02019;an</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Bath</surname><given-names>Louise</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Zalin</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Labib</surname><given-names>Mourad</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Sudhesh</given-names></name><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Simpson</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Blom</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Marais</surname><given-names>David</given-names></name><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Schwabe</surname><given-names>John</given-names></name><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><name><surname>Barroso</surname><given-names>In&#x000ea;s</given-names></name><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Trembath</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="A11">11</xref></contrib><contrib contrib-type="author"><name><surname>Wareham</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Nagy</surname><given-names>Laszlo</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gurnell</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Rahilly</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chatterjee</surname><given-names>Krishna</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Medicine, University of Cambridge, United Kingdom </aff><aff id="A2"><label>2</label>Department of Clinical Biochemistry University of Cambridge, United Kingdom </aff><aff id="A3"><label>3</label>Department of Biochemistry and Molecular Biology, University of Debrecen, Hungary </aff><aff id="A4"><label>4</label>Medical Research Council Epidemiology Unit, Cambridge, United Kingdom </aff><aff id="A5"><label>5</label>Royal Hospital for Sick Children, Edinburgh, United Kingdom </aff><aff id="A6"><label>6</label>Wordsley Hospital, Stourbridge, United Kingdom </aff><aff id="A7"><label>7</label>Department of Medicine, University of Warwick, Coventry, United Kingdom </aff><aff id="A8"><label>8</label>Department of Internal Medicine, University of Cape Town, South Africa </aff><aff id="A9"><label>9</label>Medical Research Council, Laboratory of Molecular Biology, Cambridge, United Kingdom </aff><aff id="A10"><label>10</label>Metabolic Disease Group, Wellcome Trust Sanger Institute, Cambridgeshire, United Kingdom </aff><aff id="A11"><label>11</label>Department of Medical and Molecular Genetics, King&#x02019;s College, London, United Kingdom </aff><author-notes><fn fn-type="equal" id="FN1"><label>12</label><p id="P1">These authors contributed equally to this work.</p></fn><corresp id="CR1"><label>*</label>Correspondence: <email>kkc1@mole.bio.cam.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>21</day><month>2</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2006</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>3</month><year>2007</year></pub-date><volume>4</volume><issue>4</issue><fpage>303</fpage><lpage>311</lpage><abstract><title>Summary</title><p id="P3">PPAR&#x003b3; is essential for adipogenesis and metabolic homeostasis. We describe mutations in the DNA and ligand binding domains of human PPAR&#x003b3; in lipodystrophic, severe insulin resistance. These receptor mutants lack DNA binding and transcriptional activity but can translocate to the nucleus, interact with PPAR&#x003b3; coactivators and inhibit coexpressed wild-type receptor. Expression of PPAR&#x003b3; target genes is markedly attenuated in mutation-containing versus receptor haploinsufficent primary cells, indicating that such dominant-negative inhibition operates in vivo. Our observations suggest that these mutants restrict wild-type PPAR&#x003b3; action via a non-DNA binding, transcriptional interference mechanism, which may involve sequestration of functionally limiting coactivators.</p></abstract></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P4">The nuclear receptor (NR) peroxisome proliferator-activated receptor &#x003b3; (PPAR&#x003b3;) is a ligand-inducible transcription factor that is essential for adipocyte differentiation (<xref ref-type="bibr" rid="R58">Tontonoz et al., 1994b</xref>; <xref ref-type="bibr" rid="R7">Barak et al., 1999</xref>; <xref ref-type="bibr" rid="R44">Rosen et al., 1999</xref>). Alternative splicing and differential promoter usage generates two protein isoforms: PPAR&#x003b3;2, expressed from a single &#x003b3;2 promoter, contains an additional 28 amino-terminal amino acids and is nearly adipose-specific; PPAR&#x003b3;1, whose expression can be regulated by multiple (&#x003b3;1, &#x003b3;3, &#x003b3;4) promoters, is more ubiquitously distributed. In addition to adipogenesis, PPAR&#x003b3; also plays an important role in adipocyte lipid metabolism, regulating target genes (lipoprotein lipase, fatty-acid transport protein, aquaporin) that mediate triglyceride hydrolysis and fatty acid and glycerol uptake, together with genes (acylCoA synthetase, PEPCK, glycerol kinase) involved in fatty acid re-esterification and lipid storage (<xref ref-type="bibr" rid="R32">Lehrke and Lazar, 2005</xref>; <xref ref-type="bibr" rid="R48">Savage, 2005</xref>). The thiazolidinedione (TZD) class of antidiabetic agents are synthetic, high-affinity PPAR&#x003b3; ligands (<xref ref-type="bibr" rid="R31">Lehmann et al., 1995</xref>) and putative endogenous activators include fatty acids, eicosanoids, and prostaglandin derivatives (<xref ref-type="bibr" rid="R16">Desvergne and Wahli, 1999</xref>) as well as undefined ligands produced during adipocyte differentiation (<xref ref-type="bibr" rid="R59">Tzameli et al., 2004</xref>).</p><p id="P5">The most common population genetic variant of PPAR&#x003b3; is a polymorphism replacing alanine for proline at codon 12 (Pro12Ala) in PPAR&#x003b3;2, with a meta-analysis of association studies showing that the Pro allele confers a modest but significant increase in diabetes risk (<xref ref-type="bibr" rid="R6">Altshuler et al., 2000</xref>). The discovery that PPAR&#x003b3; is a target for TZDs, which act by enhancing tissue insulin sensitivity, prompted screening of a cohort of subjects with severe insulin resistance, with identification of two missense PPAR&#x003b3; mutations (P467L, V290M) in unrelated cases (<xref ref-type="bibr" rid="R9">Barroso et al., 1999</xref>). Functional studies showed that these mutant receptors retain DNA binding but exhibit significant impairment of transcriptional activation and coactivator recruitment in response to different ligands (<xref ref-type="bibr" rid="R9">Barroso et al., 1999</xref>; <xref ref-type="bibr" rid="R3">Agostini et al., 2004</xref>), due to the mutations destabilizing the carboxyterminal &#x003b1; helix of PPAR&#x003b3; (<xref ref-type="bibr" rid="R28">Kallenberger et al., 2003</xref>), which mediates these functions. Consonant with heterozygosity in affected subjects and dominant inheritance in one kindred, the P467L and V290M mutant receptors inhibited the transcriptional activity of wild-type (WT) PPAR&#x003b3; in a dominant-negative manner (<xref ref-type="bibr" rid="R9">Barroso et al., 1999</xref>). Subsequently, two further heterozygous mutations in the ligand binding domain (LBD) of PPAR&#x003b3; (R425C; F388L) have been described, with recognition that in addition to insulin resistance the phenotype also includes a stereotyped pattern of partial lipodystrophy (PLD) (<xref ref-type="bibr" rid="R24">Hegele et al., 2002</xref>; <xref ref-type="bibr" rid="R2">Agarwal and Garg, 2002</xref>; <xref ref-type="bibr" rid="R50">Savage et al., 2003</xref>).</p><p id="P6">Following this, we described several individuals who were heterozygous for a frameshift/premature stop codon mutation, ([A<sup>553</sup>&#x00394;AAAiT]fs.185[stop186]-hereafter abbreviated to FSX) in the DNA binding domain (DBD) of PPAR&#x003b3;, with this truncation mutant lacking DNA binding, transcriptional, and dominant-negative activity. Significantly, heterozygosity for the FSX mutation alone was not associated with insulin resistance, but individuals who were doubly heterozygous, with an additional defect in an unrelated gene encoding the muscle-specific regulatory subunit of protein phosphatase 1 (PPP1R3A), exhibited severe insulin resistance (<xref ref-type="bibr" rid="R49">Savage et al., 2002</xref>). Heterozygosity for a single nucleotide substitution in the promoter of human PPAR&#x003b3;4 leading to its altered expression in vitro has been associated with PLD and insulin resistance in one family, but the authors did not exclude the possibility of interaction with a defect at a second genetic locus to produce this phenotype (<xref ref-type="bibr" rid="R5">Al-Shali et al., 2004</xref>).</p><p id="P7">Here, we describe the identification of five heterozygous human PPAR&#x003b3; mutations (C114R, C131Y, C162W, R357X, [A<sup>935</sup>&#x00394;C]fs.312[stop315]-hereafter abbreviated to FS315X) not associated with a PPP1R3A gene defect, in unrelated cases of lipodystrophic insulin resistance and show that these mutants inhibit WT receptor action via a non-DNA binding, dominant-negative mechanism.</p></sec><sec id="S2"><title>Results and Discussion</title><sec id="S3"><title>Heterozygous PPAR&#x003b3; mutations are associated with lipodystrophic insulin resistance</title><p id="P8">The case histories (see the Supplemental Data available with this article online) and characterization (<xref ref-type="table" rid="T1">Table 1</xref>) of index subjects (S1-S5) harboring PPAR&#x003b3; mutations indicate many of the features associated with previously described cases (<xref ref-type="bibr" rid="R9">Barroso et al., 1999</xref>; <xref ref-type="bibr" rid="R24">Hegele et al., 2002</xref>; <xref ref-type="bibr" rid="R2">Agarwal and Garg, 2002</xref>; <xref ref-type="bibr" rid="R50">Savage et al., 2003</xref>). All subjects showed marked fasting hyperinsulinaemia (<xref ref-type="table" rid="T1">Table 1</xref>) with acanthosis nigricans in a subset (S3, S4, S5), denoting severe insulin resistance; total body fat was reduced in all individuals, and imaging indicated a stereotyped pattern of partial lipodystrophy affecting gluteal (Figure S1) and peripheral limb depots; hepatic steatosis and marked dyslipidaemia (raised triglycerides, low high-density lipoprotein cholesterol [HDL-C]) with secondary complications (cutaneous eruptive xanthomata S3, S4; pancreatitis S5) were features of all cases; several individuals (S2, S3, S5) exhibited early-onset hypertension.</p><p id="P9">We sequenced the &#x003b3;4 promoter, coding exons and splice junctions of <italic>PPARG</italic> and identified heterozygous, missense mutations in the DBD (S1-S3), or premature stop mutations in the LBD (S4, S5) of the receptor in index cases. <italic>PPARG</italic> has also been sequenced by us in 215 additional subjects, comprising 93 patients from our severe insulin resistance cohort (<xref ref-type="bibr" rid="R9">Barroso et al., 1999</xref>), 48 CEPH individuals of European descent and 27 Europid, hyperinsulinaemic participants in the Ely study (<xref ref-type="bibr" rid="R62">Williams et al., 1995</xref>), and 47 controls from four different ethnic groups, or sequenced by others in 24 African and 23 CEPH European individuals (Seattle SNPs project, <ext-link ext-link-type="uri" xlink:href="http://pga.gs.washington.edu">http://pga.gs.washington.edu</ext-link>), and other than the Pro12Ala polymorphism neither these or other mutations have been identified. We also sequenced <italic>PPP1R3A</italic> in each proband and identified no mutations or polymorphisms, excluding a second genetic defect at this locus as described previously (<xref ref-type="bibr" rid="R49">Savage et al., 2002</xref>).</p><p id="P10">Heterozygosity for PPAR&#x003b3; mutations in a parent and grandparent of S3 and a parent of S5 segregated with phenotype, constituting a dominant inheritance pattern in two families; one sibling of S2 with dyslipidaemia and insulin resistance was heterozygous for the PPAR&#x003b3; mutation whereas another genetically unaffected sibling was biochemically normal; the ascertainable family members of S1 were unaffected and normal and no relatives of S4 could be contacted (<xref ref-type="fig" rid="F1">Figure 1B</xref>).</p></sec><sec id="S4"><title>PPAR&#x003b3; mutants fail to bind DNA and are transcriptionally inactive</title><p id="P11">Three missense mutations involve highly conserved cysteine residues within (C114R, C131Y, C162W) the DBD and two further nonsense (R357X) or frameshift/premature stop (FS315X) mutations truncate the receptor within the central part of its LBD (<xref ref-type="fig" rid="F1">Figure 1A</xref>), predicting loss-of-function of the mutant proteins. We therefore characterised and compared the properties of these PPAR&#x003b3; mutants with the FSX mutant described previously (<xref ref-type="bibr" rid="R49">Savage et al., 2002</xref>).</p><p id="P12">The receptor mutants exhibited negligible transcriptional activity, lacking constitutive basal activity noted previously with WT PPAR&#x003b3; (<xref ref-type="bibr" rid="R3">Agostini et al., 2004</xref>; <xref ref-type="bibr" rid="R64">Zamir et al., 1997</xref>) as well as any response to rosiglitazone, a TZD receptor agonist (<xref ref-type="fig" rid="F1">Figure 1C</xref>). Such complete loss of function was similar to the FSX mutant and might be anticipated with analogous truncation mutants (FS315X, R357X) not possessing the transactivation (AF2) domain at the receptor carboxyterminus (<xref ref-type="fig" rid="F1">Figure 1A</xref>) (<xref ref-type="bibr" rid="R64">Zamir et al., 1997</xref>; <xref ref-type="bibr" rid="R63">Wu et al., 2003</xref>), but the lack of function with DBD mutants (C114R, C131Y, C162W), prompted further investigation of their DNA binding properties.</p><p id="P13">PPAR&#x003b3; heterodimerizes with the retinoid X receptor (RXR) and this complex has been shown to bind a DNA response element (PPARE), consisting of a direct repeat (DR1) of the consensus sequence (AGGTCA) separated by a single nucleotide (<xref ref-type="bibr" rid="R26">Ijpenberg et al., 1997</xref>) and a recent study has suggested that the stringency of PPAR&#x003b3; binding to some response elements is relatively relaxed, not needing complete integrity of its DBD (<xref ref-type="bibr" rid="R55">Temple et al., 2005</xref>). A range of previously documented or predicted PPAREs from known target genes were therefore tested in electrophoretic mobility shift assays and both DBD and LBD truncation receptor mutants showed negligible heterodimeric binding (<xref ref-type="fig" rid="F1">Figure 1D</xref>). To examine interaction of mutant receptors with RXR, we coexpressed VP16-full length PPAR&#x003b3; fusions with Gal4DBD-RXR in a mammalian two-hybrid assay. In keeping with preservation of the dimerization interface (<xref ref-type="bibr" rid="R17">Gampe et al., 2000</xref>) within their intact LBD (<xref ref-type="fig" rid="F1">Figure 1A</xref>), the DBD mutants interacted readily whereas the FS315X, R357X, and FSX mutants lacking this interface failed to be recruited to Gal4-RXR (Figure S2). It was therefore conceivable that the DBD mutants could be recruited indirectly to a PPARE by binding RXR (<xref ref-type="bibr" rid="R17">Gampe et al., 2000</xref>), or conversely, that the LBD truncation mutants might bind a PPARE monomerically as has been documented with the thyroid hormone receptor (TR) (<xref ref-type="bibr" rid="R30">Lazar et al., 1991</xref>). However, unlike WT receptor, VP16-full length, mutant PPAR&#x003b3; fusions were unable to activate a PPARE-containing reporter gene (Figure S3), indicating that like FSX, these PPAR&#x003b3; mutants do not bind DNA directly or indirectly.</p></sec><sec id="S5"><title>PPAR&#x003b3; mutants translocate to the nucleus and interact with cofactors</title><p id="P14">The intracellular localization of WT PPAR&#x003b3; is predominantly nuclear (<xref ref-type="bibr" rid="R4">Akiyama et al., 2002</xref>) and, analogous to steroid/thyroid hormone receptors, may be dependent on a putative nuclear localisation signal (NLS) located between its DBD and LBD (<xref ref-type="fig" rid="F1">Figure 1A</xref>) (<xref ref-type="bibr" rid="R22">Guiochon-Mantel and Milgrom, 1993</xref>; <xref ref-type="bibr" rid="R66">Zhu et al., 1998</xref>). Studies of GFP-PPAR&#x003b3; fusions showed that, in keeping with preservation of the putative NLS, both DBD and LBD truncation mutants localized to the nucleus comparably to WT, whereas the FSX truncation mutant, which lacks this sequence, remained cytoplasmic similar to GFP alone (<xref ref-type="fig" rid="F1">Figure 1E</xref>).</p><p id="P15">We next examined whether the PPAR&#x003b3; mutants might also retain the ability to interact with transcriptional coactivators. Steroid receptor coactivator-1 (SRC1/NCoA1) (<xref ref-type="bibr" rid="R37">Onate et al., 1995</xref>) and PPAR&#x003b3; binding protein/thyroid receptor-associated protein 220 (PBP/TRAP220) interact directly with the AF2 domain of PPAR&#x003b3;, with the latter cofactor being required for receptor-mediated adipogenesis (<xref ref-type="bibr" rid="R67">Zhu et al., 1996</xref>, <xref ref-type="bibr" rid="R68">1997</xref>; <xref ref-type="bibr" rid="R18">Ge et al., 2002</xref>). Consistent with preservation of their AF2 domains, protein-protein interaction assays showed ligand-dependent binding of SRC1 or TRAP220 to the DBD mutants, but no specific interaction with FSX or LBD truncation mutants, which lack this region (<xref ref-type="fig" rid="F1">Figure 1F</xref>). Conversely, we hypothesized that the PPAR&#x003b3; LBD truncation mutants would retain the ability to recruit coactivators, which can interact with receptor independently of its AF2 domain. PPAR&#x003b3; coactivator-1 (PGC1), which augments receptor action in fat cells (<xref ref-type="bibr" rid="R41">Puigserver and Spiegelman, 2003</xref>), can bind PPAR&#x003b3; via its DBD and hinge region (&#x003b1;&#x003b1; 128-229) (<xref ref-type="bibr" rid="R40">Puigserver et al., 1999</xref>); PDIP, isolated in a two hybrid assay using the DBD/hinge region of PPAR&#x003b3; (<xref ref-type="bibr" rid="R56">Tomaru et al., 2006</xref>), is a coactivator that also enhances PPAR&#x003b1; activity (<xref ref-type="bibr" rid="R53">Surapureddi et al., 2002</xref>). Both PGC1 and PDIP bound WT or FS315X and R357X LBD truncation mutants in protein-protein interaction assays, whereas the FSX mutant showed negligible interaction (<xref ref-type="fig" rid="F1">Figure 1G</xref>).</p></sec><sec id="S6"><title>PPAR&#x003b3; signaling is reduced in mutation-containing primary cells ex vivo or mutant-expressing cells in vitro</title><p id="P16">The observation that these PPAR&#x003b3; mutants translocate to the nucleus and interact with coactivators raised the possibility that they might interfere with WT receptor signaling. The murine adipocyte P2 (aP2) gene is a classical target of PPAR&#x003b3; action (<xref ref-type="bibr" rid="R57">Tontonoz et al., 1994a</xref>; <xref ref-type="bibr" rid="R21">Guan et al., 2005</xref>) and the human homolog (FABP4) is similarly responsive (<xref ref-type="bibr" rid="R39">Pelton et al., 1999</xref>). When coexpressed with WT PPAR&#x003b3; at equivalent levels in 3T3-L1 adipocytes, the DBD and LBD mutants blocked WT receptor mediated activation of the human aP2/FABP4 gene promoter comparably to an artificial, dominant-negative PPAR&#x003b3; mutant (AF2) described previously (<xref ref-type="bibr" rid="R23">Gurnell et al., 2000</xref>), whereas FSX lacked dominant-negative inhibitory activity (<xref ref-type="fig" rid="F2">Figure 2A</xref>).</p><p id="P17">We wished to determine whether such divergent dominant-negative inhibition by these PPAR&#x003b3; mutants versus FSX might operate in vivo. PPAR&#x003b3; is highly expressed in immature dendritic cells (IDCs) derived from primary human blood monocytes and mediates marked receptor responsiveness, with strong ligand-dependent induction of aP2 expression in these cells (<xref ref-type="bibr" rid="R54">Szatmari et al., 2004</xref>). Induction of aP2/FABP4 expression in IDCs containing DBD or LBD PPAR&#x003b3; mutations was severely attenuated compared to responses in control cells from either normal individuals (WT) or from subjects (IR) with comparable insulin resistance without a PPAR&#x003b3; gene defect. Significantly, aP2 induction in FSX mutation-containing cells was comparable to responses from control subjects (<xref ref-type="fig" rid="F2">Figure 2B</xref>). We examined other PPAR&#x003b3; target genes, identified from extensive microarray profiling of normal IDCs (I.S. and L.N., unpublished data) and found that responses to PPAR&#x003b3; agonist in DBD and LBD truncation mutation-containing cells were markedly attenuated whereas FSX mutation-containing cells exhibited responses that were either similar or only slightly reduced compared to WT cells (<xref ref-type="fig" rid="F2">Figure 2C</xref>). PPAR&#x003b3; mRNA levels in control and mutation-containing primary cells were similar (data not shown), suggesting that differential responsiveness was not due to altered receptor expression. Furthermore, PPAR&#x003b3; mRNA from both WT and R357X alleles was expressed in mutation-containing IDCs (<xref ref-type="fig" rid="F2">Figure 2D</xref>), indicating that the R357X transcript is not subject to nonsense-mediated decay (<xref ref-type="bibr" rid="R14">Culbertson, 1999</xref>) and both WT and R357X mutant PPAR&#x003b3; proteins were also expressed in these cells (<xref ref-type="fig" rid="F2">Figure 2E</xref>).</p><p id="P18">Finally, we determined whether dominant-negative inhibition by a non-DNA binding PPAR&#x003b3; mutant could interfere with a receptor-mediated biological process. Compared to control, WT PPAR&#x003b3; or GFP adenovirus-transduced human preadipocyte cells, both cellular differentiation (<xref ref-type="fig" rid="F3">Figure 3A</xref>) and aP2 gene expression (<xref ref-type="fig" rid="F3">Figure 3B</xref>) in cells transduced with C114R mutant PPAR&#x003b3; adenovirus were significantly reduced.</p></sec><sec id="S7"><title>Transcriptional interference via a non-DNA binding mechanism</title><p id="P19">We have shown previously that dominant-negative inhibition by PPAR&#x003b3; mutants (P467L, V290M), is mediated by repression of target genes by DNA-bound mutant receptors, analogous to mechanisms of other mutant nuclear receptors (e.g., the v-erbA oncogene, TR&#x003b2; mutants in Resistance to Thyroid Hormone, PZLF-RAR&#x003b1; fusion proteins in promyelocytic leukaemia) (<xref ref-type="bibr" rid="R33">Love et al., 2000</xref>). In contrast, the missense DBD and LBD truncation mutants identified here are unable to bind DNA, yet can inhibit WT PPAR&#x003b3; action, suggesting a different mechanism of transcriptional interference. Competition for shared cofactors by NRs was postulated to explain mutual antagonism of progesterone and estrogen receptor signaling (<xref ref-type="bibr" rid="R36">Meyer et al., 1989</xref>) and the subsequent observation that SRC1, a shared coactivator, could relieve such &#x0201c;squelching&#x0201d;, validated this hypothesis (<xref ref-type="bibr" rid="R37">Onate et al., 1995</xref>). Ligand-activated NRs have been shown to inhibit either their own function (<xref ref-type="bibr" rid="R8">Barettino et al., 1994</xref>) or that of heterologous receptors (<xref ref-type="bibr" rid="R65">Zhang et al., 1996</xref>) by limiting the availability of coactivators that are recruited to their transactivation domains. Our observations indicate that non-DNA binding, dominant-negative PPAR&#x003b3; mutants can recruit coactivators, suggesting an analogous cofactor sequestration mechanism for thereby restricting WT receptor function. Evidence suggests that similar mechanisms operate to inhibit PPAR signaling in other contexts: analogous to our natural DBD mutants, others have generated artificial, dominant-negative, PPAR&#x003b3; DBD mutants, which block either adipogenesis (<xref ref-type="bibr" rid="R38">Park et al., 2003</xref>) or neural stem cell differentiation (<xref ref-type="bibr" rid="R61">Wada et al., 2006</xref>); &#x003b3;ORF4 is a newly identified human PPAR&#x003b3; splice variant with a truncated LBD (&#x003b1;&#x003b1;273), which has dominant-negative activity and is selectively overexpressed in colorectal neoplasia (<xref ref-type="bibr" rid="R45">Sabatino et al., 2005</xref>); a dominant-negative PPAR&#x003b1; splice variant with a truncated LBD (&#x003b1;&#x003b1; 174), is expressed in human tissues including liver (<xref ref-type="bibr" rid="R19">Gervois et al., 1999</xref>). Interestingly, heterozygous, non-DNA binding mutations in some nuclear receptors do not mediate a phenotype: mutations in the DBD of VDR only cause vitamin D resistance in the homozygous state (<xref ref-type="bibr" rid="R34">Malloy et al., 1999</xref>); a &#x0201c;knock-in&#x0201d; mutation in the DBD of murine TR&#x003b2; does not produce thyroid hormone resistance (<xref ref-type="bibr" rid="R52">Shibusawa et al., 2003</xref>). Possibly due to its pivotal role in regulating transcription of genes mediating both adipocyte formation and function (<xref ref-type="bibr" rid="R32">Lehrke and Lazar, 2005</xref>), we suggest that PPAR&#x003b3; signaling may be particularly sensitive to interference via the postulated &#x0201c;squelching&#x0201d; mechanism, with deleterious metabolic consequences. A corollary of this may be that even modest enhancement of normal receptor activity in key tissues could be beneficial, supporting attempts to develop partial or tissue-specific PPAR&#x003b3; agonists (<xref ref-type="bibr" rid="R42">Reginato et al., 1998</xref>; <xref ref-type="bibr" rid="R43">Rocchi et al., 2001</xref>; <xref ref-type="bibr" rid="R11">Berger et al., 2003</xref>).</p></sec></sec><sec sec-type="methods" id="S8"><title>Experimental procedures</title><sec id="S9"><title>Sequencing of PPAR&#x003b3; and PPP1R3A genes</title><p id="P20">The PPP1R3A (exons 1-4) and PPAR&#x003b3; (exons 1-6, B and promoter region of PPAR&#x003b3;4) genes were amplified using specific primers (available upon request) and sequenced as decribed previously (<xref ref-type="bibr" rid="R49">Savage et al., 2002</xref>).</p></sec><sec id="S10"><title>Construction of PPAR&#x003b3; mutants and other vectors</title><p id="P21">Full length WT and mutant PPAR&#x003b3;1 cDNAs were cloned in pGEX4T (Amersham Pharmacia Biotech), pCMX-VP16 (kind gift from R. Evans), pSG424 (<xref ref-type="bibr" rid="R46">Sadowski and Ptashne, 1989</xref>) and pEGFP-C1 (Clontech), to yield GST-PPAR&#x003b3;1, VP16-PPAR&#x003b3;1, Gal4DBD-PPAR&#x003b3; and GFP-PPAR&#x003b3;1 fusions respectively.</p></sec><sec id="S11"><title>Electrophoretic mobility shift assays</title><p id="P22">Electrophoretic mobility shift assays (EMSA) were performed as described (<xref ref-type="bibr" rid="R13">Collingwood et al., 1994</xref>) with different natural PPAREs: aP2, derived by alignment of human and murine promoter sequences (<xref ref-type="bibr" rid="R20">Graves et al., 1992</xref>); Adiponectin (<xref ref-type="bibr" rid="R27">Iwaki et al., 2003</xref>): ACoABP (<xref ref-type="bibr" rid="R25">Helledie et al., 2002</xref>); mCPT1, (<xref ref-type="bibr" rid="R35">Mascaro et al., 1998</xref>); LXRa, (<xref ref-type="bibr" rid="R29">Laffitte et al., 2001</xref>); CAP1, (<xref ref-type="bibr" rid="R10">Baumann et al., 2000</xref>); LPL, (<xref ref-type="bibr" rid="R51">Schoonjans et al., 1996</xref>); ACoAOx, (<xref ref-type="bibr" rid="R60">Varanasi et al., 1996</xref>); ACoAOx (<xref ref-type="bibr" rid="R64">Zamir et al., 1997</xref>).</p></sec><sec id="S12"><title>Transfection assays</title><p id="P23">293EBNA cells, cultured in DMEM/10%FCS were transfected with Lipofectamine2000- or calcium phosphate-mediated in 96- or 24-well plates respectively and assayed for luciferase and &#x003b2;-galactosidase activity as described (<xref ref-type="bibr" rid="R13">Collingwood et al., 1994</xref>) following 36 hr with or without ligand. 3T3-L1 adipocyte cells were cultured and transfected with Lipofectamine2000 in 24-well plates as described above.</p></sec><sec id="S13"><title>Cellular localisation of EGFP-tagged mutants</title><p id="P24">293EBNA cells, grown on glass well slides were transfected using Lipofectamine 2000 with 1&#x000b5;g of EGFP-PPAR&#x003b3;1 fusions, fixed with 4% paraformaldehyde, mounted using vectashield and fluorescence was visualized by digital microscopy.</p></sec><sec id="S14"><title>Peripheral blood monocyte purification and IDC culture</title><p id="P25">With ethical approval, monocytes were harvested from peripheral blood by Ficoll gradient centrifugation and immunomagnetic cell separation using anti-CD14-conjugated microbeads (VarioMACS; Miltenyi Biotec), resuspended in 6-well plates at a density of 1.5 &#x000d7; 10<sup>6</sup> cells/ml and cultured in RPMI 1640 plus 10% FBS containing 800U/ml GM-CSF (Leucomax) and 500U/ml IL-4 (Peprotech) to generate IDCs as described (<xref ref-type="bibr" rid="R47">Sallusto and Lanzavecchia, 1994</xref>) with or without exposure to ligand for 24 hr.</p></sec><sec id="S15"><title>Quantitative real-time PCR analysis of gene expression</title><p id="P26">100ng of total RNA from IDCs, isolated using TRIZOL (Invitrogen), was reverse transcribed and analyzed by Taqman quantitative real-time PCR (qPCR) as described (<xref ref-type="bibr" rid="R54">Szatmari et al., 2004</xref>). The sequences of primers and probes are available upon request.</p><p id="P27">Taqman qPCR low density arrays (TLDA) were used to quantify the expression of multiple target genes in IDCs, according to the manufacturer&#x02019;s instructions.</p><p id="P28">To obtain cDNA, RNA was reverse transcribed using a High Capacity cDNA Archive kit (Applied Biosystems). The following commercially available Taqman assays (Applied Biosystems) were used: ADRP/ADFP (Hs00605340_m1), APOC1 (Hs00155790_m1), CLDN1 (Hs00221623_m1), aP2/FABP4 (Hs00609791_m1), CLECSF5 (Hs00183780_m1), CD1E (Hs00229421_m1), MYO1B (Hs00362654_m1), IL1R2 (Hs00174759_m1), OAS1 (Hs00242943_m1), p30 (Hs00396457_m1), cyclophilinA/PPIA (Hs99999904_m1). The comparative Ct method was used to quantify transcripts and normalize to cyclophilinA expression levels, which did not vary with ligand treatment. Thereafter, data were further normalized to expression levels in ligand-treated WT IDC samples using GeneSpring 7.2 software (Agilent).</p></sec><sec id="S16"><title>RFLP analysis of PPAR&#x003b3; transcripts</title><p id="P29">PPAR&#x003b3; cDNAs were amplified from WT or R357X mutation-containing IDCs by RT-PCR using forward (CTCCTTGATGAATAAAGATGGGG) and reverse (ATGTCTTCAATGGGCTTCACAT) primers, the PCR products were digested with Cac8I enzyme (New England Biolabs) and analyzed by agarose gel electrophoresis.</p></sec><sec id="S17"><title>Immunoprecipitation and Western blot analysis</title><p id="P30">IDCs, harvested from 200ml of peripheral blood, were lysed in RIPA buffer containing a protease inhibitor cocktail (Roche) and cell supernatants immunoprecipitated using a mouse monoclonal anti-PPAR&#x003b3; antibody (K8713, Perseus Proteomics) and analyzed by SDS-PAGE. Western blotting was carried out using a rabbit polyclonal anti-PPAR&#x003b3; antibody (H-100, Santa Cruz Biotechnology).</p></sec><sec id="S18"><title>Adenovirus construction and expression</title><p id="P31">Recombinant type 5 adenoviruses (Ad5) expressing GFP alone or with either WT or C114R mutant PPAR&#x003b3;1 were generated using the <italic>AdEasy Vector System</italic> (Quantum Biotechnologies, Montreal), amplified and purified as described (<xref ref-type="bibr" rid="R23">Gurnell et al., 2000</xref>). 6-well plates of Chub-S7 human preadipocyte cells were cultured and infected with 2x10<sup>7</sup> pfu/well of recombinant virus 24 hr prior to differentiation in the presence of 100nM rosiglitazone as described (<xref ref-type="bibr" rid="R15">Darimont et al., 2003</xref>). Comparable infection efficiency was verified by fluorescence microscopy with subsequent qPCR analysis on days 0, 3, 5 and 7. Fully differentiated cells were fixed and stained with Oil Red-O as described (<xref ref-type="bibr" rid="R1">Adams et al., 1997</xref>).</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>2</label><media xlink:href="NIHMS197-supplement-2.pdf" xlink:type="simple" id="N0x8c66c80N0x9622230" position="anchor" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec></body><back><ack id="S19"><title>Acknowledgments</title><p>We would like to thank the Imaging Department (Royal Orthopaedic Hospital, Stanmore) for supplying control MRI data and Teturou Satoh (Gunma University) for providing PDIP1&#x003b1; ahead of publication. This work was supported by the Wellcome Trust (V.K.K.C., S.O.R., L.N., I.B., D.B.S.) and the Medical Research Council (N.J.W., J.W.R.S.).</p></ack><ref-list><title>References</title><ref id="R1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Reginato</surname><given-names>MJ</given-names></name><name><surname>Shao</surname><given-names>D</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name><name><surname>Chatterjee</surname><given-names>VKK</given-names></name></person-group><article-title>Transcriptional activation by peroxisome proliferator-activated receptor &#x003b3; is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>5128</fpage><lpage>5132</lpage><pub-id pub-id-type="pmid">9030579</pub-id></citation></ref><ref id="R2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>AK</given-names></name><name><surname>Garg</surname><given-names>A</given-names></name></person-group><article-title>A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>408</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">11788685</pub-id></citation></ref><ref id="R3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>M</given-names></name><name><surname>Gurnell</surname><given-names>M</given-names></name><name><surname>Savage</surname><given-names>DB</given-names></name><name><surname>Wood</surname><given-names>EM</given-names></name><name><surname>Smith</surname><given-names>AG</given-names></name><name><surname>Rajanayagam</surname><given-names>O</given-names></name><name><surname>Garnes</surname><given-names>KT</given-names></name><name><surname>Levinson</surname><given-names>SH</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name><name><surname>Schwabe</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma</article-title><source>Endocrinology</source><year>2004</year><volume>145</volume><fpage>1527</fpage><lpage>1538</lpage><pub-id pub-id-type="pmid">14657011</pub-id></citation></ref><ref id="R4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>TE</given-names></name><name><surname>Baumann</surname><given-names>CT</given-names></name><name><surname>Sakai</surname><given-names>S</given-names></name><name><surname>Hager</surname><given-names>GL</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><article-title>Selective intranuclear redistribution of PPAR isoforms by RXR alpha</article-title><source>Mol Endocrinol</source><year>2002</year><volume>16</volume><fpage>707</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">11923467</pub-id></citation></ref><ref id="R5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Shali</surname><given-names>K</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Knoers</surname><given-names>N</given-names></name><name><surname>Hermus</surname><given-names>AR</given-names></name><name><surname>Tack</surname><given-names>CJ</given-names></name><name><surname>Hegele</surname><given-names>RA</given-names></name></person-group><article-title>A single-base mutation in the peroxisome proliferator-activated receptor gamma4 promoter associated with altered in vitro expression and partial lipodystrophy</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>5655</fpage><lpage>5660</lpage><pub-id pub-id-type="pmid">15531525</pub-id></citation></ref><ref id="R6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Klannemark</surname><given-names>M</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Vohl</surname><given-names>MC</given-names></name><name><surname>Nemesh</surname><given-names>J</given-names></name><name><surname>Lane</surname><given-names>CR</given-names></name><name><surname>Schaffner</surname><given-names>SF</given-names></name><name><surname>Bolk</surname><given-names>S</given-names></name><name><surname>Brewer</surname><given-names>C</given-names></name><etal/></person-group><article-title>The common PPAR&#x003b3;amma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes</article-title><source>Nat Genet</source><year>2000</year><volume>26</volume><fpage>76</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10973253</pub-id></citation></ref><ref id="R7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barak</surname><given-names>Y</given-names></name><name><surname>Nelson</surname><given-names>MC</given-names></name><name><surname>Ong</surname><given-names>ES</given-names></name><name><surname>Jones</surname><given-names>YZ</given-names></name><name><surname>Ruiz-Lozano</surname><given-names>P</given-names></name><name><surname>Chien</surname><given-names>KR</given-names></name><name><surname>Koder</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><article-title>PPAR&#x003b3; is required for placental, cardiac and adipose tissue development</article-title><source>Mol Cell</source><year>1999</year><volume>4</volume><fpage>585</fpage><lpage>595</lpage><pub-id pub-id-type="pmid">10549290</pub-id></citation></ref><ref id="R8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barettino</surname><given-names>D</given-names></name><name><surname>Vivanco Ruiz</surname><given-names>MDM</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name></person-group><article-title>Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor</article-title><source>EMBO J</source><year>1994</year><volume>13</volume><fpage>3039</fpage><lpage>3049</lpage><pub-id pub-id-type="pmid">8039499</pub-id></citation></ref><ref id="R9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Gurnell</surname><given-names>M</given-names></name><name><surname>Crowley</surname><given-names>VEF</given-names></name><name><surname>Agostini</surname><given-names>M</given-names></name><name><surname>Schwabe</surname><given-names>JW</given-names></name><name><surname>Soos</surname><given-names>MA</given-names></name><name><surname>Maslen</surname><given-names>GLI</given-names></name><name><surname>Williams</surname><given-names>TDM</given-names></name><name><surname>Lewis</surname><given-names>H</given-names></name><name><surname>Schafer</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Dominant negative mutations in human PPAR&#x003b3; are associated with severe insulin resistance, diabetes mellitus and hypertension</article-title><source>Nature</source><year>1999</year><volume>402</volume><fpage>880</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">10622252</pub-id></citation></ref><ref id="R10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>CA</given-names></name><name><surname>Chokshi</surname><given-names>N</given-names></name><name><surname>Saltiel</surname><given-names>AR</given-names></name><name><surname>Ribon</surname><given-names>V</given-names></name></person-group><article-title>Cloning and characterization of a functional peroxisome proliferator activator receptor-gamma-responsive element in the promoter of the CAP gene</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>9131</fpage><lpage>9135</lpage><pub-id pub-id-type="pmid">10734046</pub-id></citation></ref><ref id="R11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JP</given-names></name><name><surname>Petro</surname><given-names>AE</given-names></name><name><surname>Macnaul</surname><given-names>KL</given-names></name><name><surname>Kelly</surname><given-names>LJ</given-names></name><name><surname>Zhang</surname><given-names>BB</given-names></name><name><surname>Richards</surname><given-names>K</given-names></name><name><surname>Elbrecht</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>BA</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Doebber</surname><given-names>TW</given-names></name><etal/></person-group><article-title>Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator</article-title><source>Mol Endocrinol</source><year>2003</year><volume>17</volume><fpage>662</fpage><lpage>676</lpage><pub-id pub-id-type="pmid">12554792</pub-id></citation></ref><ref id="R12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>D</given-names></name><name><surname>James</surname><given-names>WPT</given-names></name><name><surname>Besser</surname><given-names>GM</given-names></name><name><surname>Brock</surname><given-names>CGD</given-names></name><name><surname>Craddock</surname><given-names>D</given-names></name><name><surname>Garrow</surname><given-names>JS</given-names></name><name><surname>Hockaday</surname><given-names>TDR</given-names></name><name><surname>Lewis</surname><given-names>B</given-names></name><name><surname>Pilkington</surname><given-names>TRE</given-names></name><name><surname>Silverstone</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Obesity: Areport of the College of Physicians</article-title><source>J Roy Coll Phys London</source><year>1983</year><volume>17</volume><fpage>5</fpage><lpage>65</lpage></citation></ref><ref id="R13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collingwood</surname><given-names>TN</given-names></name><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Tone</surname><given-names>Y</given-names></name><name><surname>Chatterjee</surname><given-names>VKK</given-names></name></person-group><article-title>Spectrum of transcriptional dimerization and dominant negative properties of twenty different mutant thyroid hormone &#x003b2; receptors in thyroid hormone resistance syndrome</article-title><source>Mol Endocrinol</source><year>1994</year><volume>8</volume><fpage>1262</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">7838159</pub-id></citation></ref><ref id="R14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Culbertson</surname><given-names>MR</given-names></name></person-group><article-title>RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer</article-title><source>Trends Genet</source><year>1999</year><volume>15</volume><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10098411</pub-id></citation></ref><ref id="R15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darimont</surname><given-names>C</given-names></name><name><surname>Zbinden</surname><given-names>I</given-names></name><name><surname>Avanti</surname><given-names>O</given-names></name><name><surname>Leone-Vautravers</surname><given-names>P</given-names></name><name><surname>Giusti</surname><given-names>V</given-names></name><name><surname>Burckhardt</surname><given-names>P</given-names></name><name><surname>Pfeifer</surname><given-names>AM</given-names></name><name><surname>Mace</surname><given-names>K</given-names></name></person-group><article-title>Reconstitution of telomerase activity combined with HPV-E7 expression allow human preadipocytes to preserve their differentiation capacity after immortalization</article-title><source>Cell Death Differ</source><year>2003</year><volume>10</volume><fpage>1025</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">12934077</pub-id></citation></ref><ref id="R16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desvergne</surname><given-names>B</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptors: nuclear control of metabolism</article-title><source>Endocr Rev</source><year>1999</year><volume>20</volume><fpage>649</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">10529898</pub-id></citation></ref><ref id="R17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gampe</surname><given-names>JRT</given-names></name><name><surname>Montana</surname><given-names>VG</given-names></name><name><surname>Lambert</surname><given-names>MH</given-names></name><name><surname>Miller</surname><given-names>AB</given-names></name><name><surname>Bledsoe</surname><given-names>RK</given-names></name><name><surname>Milburn</surname><given-names>MV</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name></person-group><article-title>Asymmetry in the PPAR&#x003b3;/RXR&#x003b1; crystal structure reveals the molecular basis of heterodimerization among nuclear receptors</article-title><source>Mol Cell</source><year>2000</year><volume>5</volume><fpage>545</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">10882139</pub-id></citation></ref><ref id="R18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>K</given-names></name><name><surname>Guermah</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>CX</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Wallberg</surname><given-names>AE</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>Roeder</surname><given-names>RG</given-names></name></person-group><article-title>Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis</article-title><source>Nature</source><year>2002</year><volume>417</volume><fpage>563</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">12037571</pub-id></citation></ref><ref id="R19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gervois</surname><given-names>P</given-names></name><name><surname>Torra</surname><given-names>IP</given-names></name><name><surname>Chinetti</surname><given-names>G</given-names></name><name><surname>Grotzinger</surname><given-names>T</given-names></name><name><surname>Dubois</surname><given-names>G</given-names></name><name><surname>Fruchart</surname><given-names>JC</given-names></name><name><surname>Fruchart-Najib</surname><given-names>J</given-names></name><name><surname>Leitersdorf</surname><given-names>E</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name></person-group><article-title>A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity</article-title><source>Mol Endocrinol</source><year>1999</year><volume>13</volume><fpage>1535</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">10478844</pub-id></citation></ref><ref id="R20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graves</surname><given-names>RA</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Platt</surname><given-names>KA</given-names></name><name><surname>Ross</surname><given-names>SR</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Identification of a fat cell enhancer: analysis of requirements for adipose tissue-specific gene expression</article-title><source>J Cell Biochem</source><year>1992</year><volume>49</volume><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">1644859</pub-id></citation></ref><ref id="R21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>HP</given-names></name><name><surname>Ishizuka</surname><given-names>T</given-names></name><name><surname>Chui</surname><given-names>PC</given-names></name><name><surname>Lehrke</surname><given-names>M</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name></person-group><article-title>Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes</article-title><source>Genes Dev</source><year>2005</year><volume>19</volume><fpage>453</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">15681609</pub-id></citation></ref><ref id="R22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guiochon-Mantel</surname><given-names>A</given-names></name><name><surname>Milgrom</surname><given-names>E</given-names></name></person-group><article-title>Cytoplasmic-nuclear trafficking of steroid hormone receptors</article-title><source>Tr Endocrinol Metab</source><year>1993</year><volume>10</volume><fpage>322</fpage><lpage>328</lpage></citation></ref><ref id="R23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gurnell</surname><given-names>M</given-names></name><name><surname>Wentworth</surname><given-names>JM</given-names></name><name><surname>Agostini</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>M</given-names></name><name><surname>Collingwood</surname><given-names>TN</given-names></name><name><surname>Provenzano</surname><given-names>C</given-names></name><name><surname>Browne</surname><given-names>PO</given-names></name><name><surname>Rajanayagam</surname><given-names>O</given-names></name><name><surname>Burris</surname><given-names>TP</given-names></name><name><surname>Schwabe</surname><given-names>JW</given-names></name><etal/></person-group><article-title>A dominant negative Peroxisome Proliferator-activated Receptor &#x003b3; (PPAR&#x003b3;) mutant is a constitutive repressor and inhibits PPAR&#x003b3;-mediated adipogenesis</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>5754</fpage><lpage>5759</lpage><pub-id pub-id-type="pmid">10681562</pub-id></citation></ref><ref id="R24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hegele</surname><given-names>RA</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Frankowski</surname><given-names>C</given-names></name><name><surname>Mathews</surname><given-names>ST</given-names></name><name><surname>Leff</surname><given-names>T</given-names></name></person-group><article-title>PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>3586</fpage><lpage>3590</lpage><pub-id pub-id-type="pmid">12453919</pub-id></citation></ref><ref id="R25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helledie</surname><given-names>T</given-names></name><name><surname>Grontved</surname><given-names>L</given-names></name><name><surname>Jensen</surname><given-names>SS</given-names></name><name><surname>Kiilerich</surname><given-names>P</given-names></name><name><surname>Rietveld</surname><given-names>L</given-names></name><name><surname>Albrektsen</surname><given-names>T</given-names></name><name><surname>Boysen</surname><given-names>MS</given-names></name><name><surname>Nohr</surname><given-names>J</given-names></name><name><surname>Larsen</surname><given-names>LK</given-names></name><name><surname>Fleckner</surname><given-names>J</given-names></name><etal/></person-group><article-title>The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>26821</fpage><lpage>26830</lpage><pub-id pub-id-type="pmid">12015306</pub-id></citation></ref><ref id="R26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ijpenberg</surname><given-names>A</given-names></name><name><surname>Jeannin</surname><given-names>E</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name><name><surname>Desvergne</surname><given-names>B</given-names></name></person-group><article-title>Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>20108</fpage><lpage>20117</lpage><pub-id pub-id-type="pmid">9242684</pub-id></citation></ref><ref id="R27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwaki</surname><given-names>M</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><name><surname>Maeda</surname><given-names>N</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Makishima</surname><given-names>M</given-names></name><name><surname>Shimomura</surname><given-names>I</given-names></name></person-group><article-title>Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>1655</fpage><lpage>1663</lpage><pub-id pub-id-type="pmid">12829629</pub-id></citation></ref><ref id="R28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kallenberger</surname><given-names>BC</given-names></name><name><surname>Love</surname><given-names>JD</given-names></name><name><surname>Chatterjee</surname><given-names>VK</given-names></name><name><surname>Schwabe</surname><given-names>JW</given-names></name></person-group><article-title>A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease</article-title><source>Nat Struct Biol</source><year>2003</year><volume>10</volume><fpage>136</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">12536206</pub-id></citation></ref><ref id="R29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laffitte</surname><given-names>BA</given-names></name><name><surname>Joseph</surname><given-names>SB</given-names></name><name><surname>Walczak</surname><given-names>R</given-names></name><name><surname>Pei</surname><given-names>L</given-names></name><name><surname>Wilpitz</surname><given-names>DC</given-names></name><name><surname>Collins</surname><given-names>JL</given-names></name><name><surname>Tontonoz</surname><given-names>P</given-names></name></person-group><article-title>Autoregulation of the human liver X receptor alpha promoter</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>7558</fpage><lpage>7568</lpage><pub-id pub-id-type="pmid">11604492</pub-id></citation></ref><ref id="R30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazar</surname><given-names>MA</given-names></name><name><surname>Berrodin</surname><given-names>TJ</given-names></name><name><surname>Harding</surname><given-names>HP</given-names></name></person-group><article-title>Differential DNA binding by monomeric, homodimeric, and potentially heteromeric forms of the thyroid hormone receptor</article-title><source>Mol Cell Biol</source><year>1991</year><volume>11</volume><fpage>5005</fpage><lpage>5015</lpage><pub-id pub-id-type="pmid">1922030</pub-id></citation></ref><ref id="R31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>JM</given-names></name><name><surname>Moore</surname><given-names>LB</given-names></name><name><surname>Smith-Oliver</surname><given-names>TA</given-names></name><name><surname>Wilkison</surname><given-names>WO</given-names></name><name><surname>Willson</surname><given-names>TM</given-names></name><name><surname>Kliewer</surname><given-names>SA</given-names></name></person-group><article-title>An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor &#x003b3; (PPAR&#x003b3;)</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>12953</fpage><lpage>12956</lpage><pub-id pub-id-type="pmid">7768881</pub-id></citation></ref><ref id="R32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehrke</surname><given-names>M</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name></person-group><article-title>The many faces of PPARgamma</article-title><source>Cell</source><year>2005</year><volume>123</volume><fpage>993</fpage><lpage>999</lpage><pub-id pub-id-type="pmid">16360030</pub-id></citation></ref><ref id="R33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>JD</given-names></name><name><surname>Gooch</surname><given-names>JT</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name><name><surname>Chatterjee</surname><given-names>VKK</given-names></name><name><surname>Schwabe</surname><given-names>JWR</given-names></name></person-group><article-title>Transcriptional repression by nuclear receptors: mechanisms and role in disease</article-title><source>Biochem Soc Trans</source><year>2000</year><volume>28</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">10961926</pub-id></citation></ref><ref id="R34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malloy</surname><given-names>PJ</given-names></name><name><surname>Pike</surname><given-names>JW</given-names></name><name><surname>Feldman</surname><given-names>D</given-names></name></person-group><article-title>The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets</article-title><source>Endocr Rev</source><year>1999</year><volume>20</volume><fpage>156</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">10204116</pub-id></citation></ref><ref id="R35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mascaro</surname><given-names>C</given-names></name><name><surname>Acosta</surname><given-names>E</given-names></name><name><surname>Ortiz</surname><given-names>JA</given-names></name><name><surname>Marrero</surname><given-names>PF</given-names></name><name><surname>Hegardt</surname><given-names>FG</given-names></name><name><surname>Haro</surname><given-names>D</given-names></name></person-group><article-title>Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>8560</fpage><lpage>8563</lpage><pub-id pub-id-type="pmid">9535828</pub-id></citation></ref><ref id="R36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>ME</given-names></name><name><surname>Gronemeyer</surname><given-names>H</given-names></name><name><surname>Turcotte</surname><given-names>B</given-names></name><name><surname>Bocquel</surname><given-names>MT</given-names></name><name><surname>Tasset</surname><given-names>D</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><article-title>Steroid hormone receptors compete for factors that mediate their enhancer function</article-title><source>Cell</source><year>1989</year><volume>57</volume><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">2720778</pub-id></citation></ref><ref id="R37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onate</surname><given-names>SA</given-names></name><name><surname>Tsai</surname><given-names>SY</given-names></name><name><surname>Tsai</surname><given-names>M-J</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>BW</given-names></name></person-group><article-title>Sequence and characterization of a coactivator for the steroid hormone receptor superfamily</article-title><source>Science</source><year>1995</year><volume>270</volume><fpage>1354</fpage><lpage>1357</lpage><pub-id pub-id-type="pmid">7481822</pub-id></citation></ref><ref id="R38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Freedman</surname><given-names>BD</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name></person-group><article-title>A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells</article-title><source>Diabetologia</source><year>2003</year><volume>46</volume><fpage>365</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">12687335</pub-id></citation></ref><ref id="R39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pelton</surname><given-names>PD</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Demarest</surname><given-names>KT</given-names></name><name><surname>Burris</surname><given-names>TP</given-names></name></person-group><article-title>PPAR&#x003b3; activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>261</volume><fpage>456</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">10425206</pub-id></citation></ref><ref id="R40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Adelmant</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>B</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Activation of PPARgamma coactivator-1 through transcription factor docking</article-title><source>Science</source><year>1999</year><volume>286</volume><fpage>1368</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">10558993</pub-id></citation></ref><ref id="R41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puigserver</surname><given-names>P</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator</article-title><source>Endocr Rev</source><year>2003</year><volume>24</volume><fpage>78</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12588810</pub-id></citation></ref><ref id="R42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reginato</surname><given-names>MJ</given-names></name><name><surname>Bailey</surname><given-names>ST</given-names></name><name><surname>Krakow</surname><given-names>SL</given-names></name><name><surname>Minami</surname><given-names>C</given-names></name><name><surname>Ishii</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name></person-group><article-title>A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor &#x003b3;-activating properties</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>32679</fpage><lpage>32684</lpage><pub-id pub-id-type="pmid">9830009</pub-id></citation></ref><ref id="R43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rocchi</surname><given-names>S</given-names></name><name><surname>Picard</surname><given-names>F</given-names></name><name><surname>Vamecq</surname><given-names>J</given-names></name><name><surname>Gelman</surname><given-names>L</given-names></name><name><surname>Potier</surname><given-names>N</given-names></name><name><surname>Zeyer</surname><given-names>D</given-names></name><name><surname>Dubuquoy</surname><given-names>L</given-names></name><name><surname>Bac</surname><given-names>P</given-names></name><name><surname>Champy</surname><given-names>MF</given-names></name><name><surname>Plunket</surname><given-names>KD</given-names></name><etal/></person-group><article-title>A unique PPAR-gamma ligand with potent insulin-sensitizing yet weak adipogenic activity</article-title><source>Mol Cell</source><year>2001</year><volume>8</volume><fpage>737</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">11684010</pub-id></citation></ref><ref id="R44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>ED</given-names></name><name><surname>Sarraf</surname><given-names>P</given-names></name><name><surname>Troy</surname><given-names>AE</given-names></name><name><surname>Bradwin</surname><given-names>G</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><name><surname>Milstone</surname><given-names>DS</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>Mortensen</surname><given-names>RM</given-names></name></person-group><article-title>PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro</article-title><source>Mol Cell</source><year>1999</year><volume>4</volume><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">10549292</pub-id></citation></ref><ref id="R45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sabatino</surname><given-names>L</given-names></name><name><surname>Casamassimi</surname><given-names>A</given-names></name><name><surname>Peluso</surname><given-names>G</given-names></name><name><surname>Barone</surname><given-names>MV</given-names></name><name><surname>Capaccio</surname><given-names>D</given-names></name><name><surname>Migliore</surname><given-names>C</given-names></name><name><surname>Bonelli</surname><given-names>P</given-names></name><name><surname>Pedicini</surname><given-names>A</given-names></name><name><surname>Febbraro</surname><given-names>A</given-names></name><name><surname>Ciccodicola</surname><given-names>A</given-names></name><etal/></person-group><article-title>A novel peroxisome proliferator-activated receptor gamma isoform with dominant negative activity generated by alternative splicing</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>26517</fpage><lpage>26525</lpage><pub-id pub-id-type="pmid">15857827</pub-id></citation></ref><ref id="R46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadowski</surname><given-names>I</given-names></name><name><surname>Ptashne</surname><given-names>M</given-names></name></person-group><article-title>A vector for expressing GAL4(1-147) fusions in mammalian cells</article-title><source>Nucleic Acids Res</source><year>1989</year><volume>17</volume><fpage>7539</fpage><pub-id pub-id-type="pmid">2798115</pub-id></citation></ref><ref id="R47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><article-title>Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha</article-title><source>J Exp Med</source><year>1994</year><volume>179</volume><fpage>1109</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">8145033</pub-id></citation></ref><ref id="R48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>DB</given-names></name></person-group><article-title>PPARgamma as a metabolic regulator: insights from genomics and pharmacology</article-title><source>Expert Rev Mol Med</source><year>2005</year><volume>2005</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15673477</pub-id></citation></ref><ref id="R49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>DB</given-names></name><name><surname>Agostini</surname><given-names>M</given-names></name><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Gurnell</surname><given-names>M</given-names></name><name><surname>Luan</surname><given-names>J</given-names></name><name><surname>Meirhaeghe</surname><given-names>A</given-names></name><name><surname>Harding</surname><given-names>AH</given-names></name><name><surname>Ihrke</surname><given-names>G</given-names></name><name><surname>Rajanayagam</surname><given-names>O</given-names></name><name><surname>Soos</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Digenic inheritance of severe insulin resistance in a human pedigree</article-title><source>Nat Genet</source><year>2002</year><volume>31</volume><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">12118251</pub-id></citation></ref><ref id="R50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>DB</given-names></name><name><surname>Tan</surname><given-names>GD</given-names></name><name><surname>Acerini</surname><given-names>CL</given-names></name><name><surname>Jebb</surname><given-names>SA</given-names></name><name><surname>Agostini</surname><given-names>M</given-names></name><name><surname>Gurnell</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>RL</given-names></name><name><surname>Umpleby</surname><given-names>AM</given-names></name><name><surname>Thomas</surname><given-names>EL</given-names></name><name><surname>Bell</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>910</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">12663460</pub-id></citation></ref><ref id="R51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoonjans</surname><given-names>K</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name></person-group><article-title>Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression</article-title><source>J Lipid Res</source><year>1996</year><volume>37</volume><fpage>907</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">8725145</pub-id></citation></ref><ref id="R52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shibusawa</surname><given-names>N</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Nikrodhanond</surname><given-names>AA</given-names></name><name><surname>Liberman</surname><given-names>MC</given-names></name><name><surname>Applebury</surname><given-names>ML</given-names></name><name><surname>Liao</surname><given-names>XH</given-names></name><name><surname>Robbins</surname><given-names>JT</given-names></name><name><surname>Refetoff</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>RN</given-names></name><name><surname>Wondisford</surname><given-names>FE</given-names></name></person-group><article-title>Thyroid hormone action in the absence of thyroid hormone receptor DNA-binding in vivo</article-title><source>J Clin Invest</source><year>2003</year><volume>112</volume><fpage>588</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">12925699</pub-id></citation></ref><ref id="R53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Surapureddi</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Bu</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Yeldandi</surname><given-names>AV</given-names></name><name><surname>Kashireddy</surname><given-names>P</given-names></name><name><surname>Cherkaoui-Malki</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>YJ</given-names></name><name><surname>Rao</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha -interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>11836</fpage><lpage>11841</lpage><pub-id pub-id-type="pmid">12189208</pub-id></citation></ref><ref id="R54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szatmari</surname><given-names>I</given-names></name><name><surname>Gogolak</surname><given-names>P</given-names></name><name><surname>Im</surname><given-names>JS</given-names></name><name><surname>Dezso</surname><given-names>B</given-names></name><name><surname>Rajnavolgyi</surname><given-names>E</given-names></name><name><surname>Nagy</surname><given-names>L</given-names></name></person-group><article-title>Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion</article-title><source>Immunity</source><year>2004</year><volume>21</volume><fpage>95</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">15345223</pub-id></citation></ref><ref id="R55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Temple</surname><given-names>KA</given-names></name><name><surname>Cohen</surname><given-names>RN</given-names></name><name><surname>Wondisford</surname><given-names>SR</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Deplewski</surname><given-names>D</given-names></name><name><surname>Wondisford</surname><given-names>FE</given-names></name></person-group><article-title>An intact DNA-binding domain is not required for peroxisome proliferator-activated receptor gamma (PPARgamma) binding and activation on some PPAR response elements</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>3529</fpage><lpage>3540</lpage><pub-id pub-id-type="pmid">15572375</pub-id></citation></ref><ref id="R56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomaru</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Yoshino</surname><given-names>S</given-names></name><name><surname>Ishizuka</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Monden</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name></person-group><article-title>Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma</article-title><source>Endocrinology</source><year>2006</year><volume>147</volume><fpage>377</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">16239304</pub-id></citation></ref><ref id="R57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Graves</surname><given-names>RA</given-names></name><name><surname>Budavari</surname><given-names>AI</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>mPPAR&#x003b3;2: tissue-specific regulator of an adipocyte enhancer</article-title><source>Genes Dev</source><year>1994a</year><volume>8</volume><fpage>1224</fpage><lpage>1234</lpage><pub-id pub-id-type="pmid">7926726</pub-id></citation></ref><ref id="R58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Stimulation of adipogenesis in fibroblasts by PPAR&#x003b3;2, a lipid-activated transcription factor</article-title><source>Cell</source><year>1994b</year><volume>79</volume><fpage>1147</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">8001151</pub-id></citation></ref><ref id="R59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tzameli</surname><given-names>I</given-names></name><name><surname>Fang</surname><given-names>H</given-names></name><name><surname>Ollero</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Hamm</surname><given-names>JK</given-names></name><name><surname>Kievit</surname><given-names>P</given-names></name><name><surname>Hollenberg</surname><given-names>AN</given-names></name><name><surname>Flier</surname><given-names>JS</given-names></name></person-group><article-title>Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>36093</fpage><lpage>36102</lpage><pub-id pub-id-type="pmid">15190061</pub-id></citation></ref><ref id="R60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varanasi</surname><given-names>U</given-names></name><name><surname>Chu</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Castellon</surname><given-names>R</given-names></name><name><surname>Yeldandi</surname><given-names>AV</given-names></name><name><surname>Reddy</surname><given-names>JK</given-names></name></person-group><article-title>Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>2147</fpage><lpage>2155</lpage><pub-id pub-id-type="pmid">8567672</pub-id></citation></ref><ref id="R61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>A</given-names></name><name><surname>Katayama</surname><given-names>K</given-names></name><name><surname>Kudo</surname><given-names>C</given-names></name><name><surname>Shibuya</surname><given-names>A</given-names></name><name><surname>Kubota</surname><given-names>N</given-names></name><name><surname>Terauchi</surname><given-names>Y</given-names></name><name><surname>Tachibana</surname><given-names>M</given-names></name><name><surname>Miyoshi</surname><given-names>H</given-names></name><name><surname>Kamisaki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor gamma -mediated regulation of neural stem cell proliferation and differentiation</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>12673</fpage><lpage>12681</lpage><pub-id pub-id-type="pmid">16524877</pub-id></citation></ref><ref id="R62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Brown</surname><given-names>DC</given-names></name><name><surname>Byrne</surname><given-names>CD</given-names></name><name><surname>Clark</surname><given-names>PM</given-names></name><name><surname>Cox</surname><given-names>BD</given-names></name><name><surname>Cox</surname><given-names>LJ</given-names></name><name><surname>Day</surname><given-names>NE</given-names></name><name><surname>Hales</surname><given-names>CN</given-names></name><name><surname>Palmer</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Undiagnosed gluocse intolerance in the community: The Isle of Ely Diabetes Project</article-title><source>Diabet Med</source><year>1995</year><volume>12</volume><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">7712700</pub-id></citation></ref><ref id="R63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Chin</surname><given-names>WW</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Burris</surname><given-names>TP</given-names></name></person-group><article-title>Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor gamma</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>8637</fpage><lpage>8644</lpage><pub-id pub-id-type="pmid">12502716</pub-id></citation></ref><ref id="R64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zamir</surname><given-names>I</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lazar</surname><given-names>MA</given-names></name></person-group><article-title>Stoichiometric and steric principles governing repression by nuclear hormone receptors</article-title><source>Genes Dev</source><year>1997</year><volume>11</volume><fpage>835</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">9106656</pub-id></citation></ref><ref id="R65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Jeyakumar</surname><given-names>M</given-names></name><name><surname>Bagchi</surname><given-names>MK</given-names></name></person-group><article-title>Ligand-dependent cross-talk between steroid and thyroid hormone receptors. Evidence for common transcriptional coactivator(s)</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>14825</fpage><lpage>14833</lpage><pub-id pub-id-type="pmid">8662980</pub-id></citation></ref><ref id="R66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XG</given-names></name><name><surname>Hanover</surname><given-names>JA</given-names></name><name><surname>Hager</surname><given-names>GL</given-names></name><name><surname>Cheng</surname><given-names>SY</given-names></name></person-group><article-title>Hormone-induced translocation of thyroid hormone receptors in living cells visualized using a receptor green fluorescent protein chimera</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>27058</fpage><lpage>27063</lpage><pub-id pub-id-type="pmid">9765220</pub-id></citation></ref><ref id="R67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Calandra</surname><given-names>C</given-names></name><name><surname>Rao</surname><given-names>MS</given-names></name><name><surname>Reddy</surname><given-names>JK</given-names></name></person-group><article-title>Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma</article-title><source>Gene Expr</source><year>1996</year><volume>6</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">9041124</pub-id></citation></ref><ref id="R68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>MS</given-names></name><name><surname>Reddy</surname><given-names>JK</given-names></name></person-group><article-title>Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>25500</fpage><lpage>25506</lpage><pub-id pub-id-type="pmid">9325263</pub-id></citation></ref></ref-list><sec id="S20" sec-type="display-objects"><title>Figures and Table</title><fig id="F1" position="float"><label>Figure 1</label><caption><p>Identification and characterization of loss-of-function mutations in human PPAR&#x003b3;</p><p><bold>A)</bold> Schematic representation of the three major domains of PPAR&#x003b3;, showing the locations of the five mutations (C114R, C131Y, C162W, FS315X, and R357X-PPAR&#x003b3;1 nomenclature) and the previously reported FSX mutation. NLS, nuclear localisation signal; RXR ID, retinoid X receptor interaction domain; AF2, activation function 2 domain.</p><p><bold>B)</bold> Family pedigrees showing genotypes (N, wild-type allele; M, mutant allele; NA, not available) and phenotypes (colored segments denote the presence of specific traits: green, type 2 diabetes mellitus/impaired glucose tolerance/hyperinsulinaemia; yellow, hypertriglyceridaemia; blue, hypertension; red, ischemic heart disease). Squares and circles represent male and female family members; slashed symbols denote deceased family members and arrows denote probands.</p><p><bold>C)</bold> PPAR&#x003b3; mutants are unable to mediate ligand-dependent transactivation. 293EBNA cells were transfected with 100 ng of wild-type (WT), mutant, or empty (pcDNA3) expression vectors, together with 500 ng of (PPARE)<sub>3</sub>TKLUC reporter construct and 100 ng of Bos-&#x003b2;-gal internal control plasmid, and increasing concentrations of rosiglitazone. Results are expressed as a percentage of the maximum activation with WT PPAR&#x003b3;1 and represent the mean &#x000b1; SEM of at least three independent experiments in triplicate.</p><p><bold>D)</bold> PPAR&#x003b3; mutants are unable to bind to DNA. EMSA with in vitro translated wild-type (WT) or mutant PPAR&#x003b3;1 (C114R, C131Y, C162W, FS315X, R357X, or FSX) and RXR proteins coincubated with oligonucleotide duplexes corresponding to various natural PPAREs. aP2, adipocyte protein 2; ACoABP, acyl coenzyme A binding protein; mCPT1, muscle carnitine palmitoyl transferase 1; LXR&#x003b1;, liver X receptor a; CAP, cbl-associated protein; LPL, lipoprotein lipase, ACoAOx, acyl coenzyme A oxidase; h, human; m, mouse; r, rat; RL, reticulocyte lysate.</p><p><bold>E)</bold> The C114R, C131Y, C162W, FS315X, and R357X mutants translocate to the nucleus whereas the FSX mutant remains cytoplasmic. 293EBNA cells were transfected as described. Top panels show DAPI-staining (blue) of nuclei, middle panels the cellular localisation of GFP-tagged receptors, and lower panels merged images.</p><p><bold>F)</bold> The DBD PPAR&#x003b3; mutants recruit SRC1 and TRAP220 coactivators, whereas the FS315X, R357X, and FSX truncation mutants do not interact. GST alone or WT and mutant GST-PPAR&#x003b3; fusion proteins were tested with <sup>35</sup>S-labeled in vitro translated SRC1 (upper panel) or TRAP220 (lower panel) in the absence or presence of rosiglitazone. Coomassie-stained gels confirmed comparable protein loading (data not shown). <bold>G)</bold> The LBD truncation mutants (FS315X, R357X) recruit PGC1&#x003b1; and PDIP1&#x003b1; coactivators, whereas the FSX mutant fails to interact. GST alone or WT and mutant GST-PPAR&#x003b3; fusion proteins were tested with <sup>35</sup>S-labeled in vitro translated human PGC1&#x003b1; and human PDIP1&#x003b1; in the absence of ligand. Coomassie-stained gels confirmed comparable protein loading (data not shown).</p></caption><graphic xlink:href="nihms-197-0001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>PPAR&#x003b3; mutants exhibit dominant-negative activity</p><p><bold>A)</bold> The C114R, C131Y, C162W, FS315X, and R357X PPAR&#x003b3; mutants inhibit transactivation by wild-type (WT) receptor, comparably to AF2, an artificial PPAR&#x003b3; mutant described previously, whereas the FSX mutant lacks dominant-negative activity (upper panel). 3T3-L1 cells were cotransfected with 33 ng of WT receptor plus an equal amount of either empty (pcDNA3) or WT or mutant expression vector, together with 265 ng of human aP2LUC reporter plasmid and 65 ng of the internal control plasmid Bos-&#x003b2;-gal. The dotted and dashed lines denote transcriptional activity of WT receptor in the absence and presence of ligand respectively. Results are expessed as fold induction relative to empty vector (pcDNA3 + pcDNA3) and represent the mean &#x000b1; SEM of at least three independent experiments in triplicate. Expression of wild-type and mutant receptor proteins was confirmed by Western blotting (lower panel) and the positions of WT, C114R, C131Y, C162W, and AF2 PPAR&#x003b3; (open arrow) and FSX, FS315X and R357X truncation mutants (solid arrows) are indicated.</p><p><bold>B and C)</bold> Ligand-dependent regulation of PPAR&#x003b3; target genes in IDCs from subjects with PPAR&#x003b3; mutations. <bold>(B)</bold>Induction of the aP2 gene by rosiglitazone, measured by qPCR, is markedly impaired in IDCs derived from subjects with the C114R, C131Y, FS315X, and R357X mutations, compared to responses in cells from normal (WT), severely insulin resistant (IR) subjects without mutations in PPAR&#x003b3; and cells with the FSX, haploinsufficient, mutation. Results represent the mean &#x000b1; SEM of more than three independent experiments in triplicate, except for cells with the FS315X mutation where a single representative experiment is shown. <bold>(C)</bold> Relative expression of several PPAR&#x003b3; target genes (5 downregulated and 5 upregulated) in WT and mutation-containing (FSX, C114R, R357X) IDCs, measured by qPCR using TLDA. Red indicates higher, and blue lower, levels of gene expression relative to rosiglitazone-treated (1000 nM) WT cells, whose responses are uniformly designated yellow. Fold changes in expression of each gene in rosiglitazone (RSG) versus vehicle (DMSO) treated WT cells are also listed.</p><p><bold>D and E)</bold> The R357X PPAR&#x003b3; mutant is expressed in IDCs. <bold>(D)</bold> PPAR&#x003b3; cDNA flanking the R357 codon was amplified by RT-PCR in IDCs from patient S5 and a control subject. Cac81 enzyme digestion of PCR products derived from the WT allele yields two fragments (161 and 74 bp), whereas abolition of this restriction site in the R357X mutant allele yields a larger 235 bp product. <bold>(E)</bold> Whole-cell lysates of WT and R357X mutant IDCs and 293EBNA cells transfected with R357X mutant were immunoprecipitated and Western blotted. The positions of WT PPAR&#x003b3; (open arrow), R357X (solid arrow), and nonspecific bands (solid arrowheads) are indicated.</p></caption><graphic xlink:href="nihms-197-0002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Adenoviral-mediated expression of the C114R PPAR&#x003b3; mutant inhibits human preadipocyte differentiation</p><p>Chub-S7 human preadipocyte cells were infected with comparable efficiency using recombinant adenoviruses expressing GFP, GFP-WT, or GFP-C114R mutant PPAR&#x003b3; and differentiated in the presence of rosiglitazone (100nM).</p><p><bold>A)</bold> Fully differentiated Chub-S7 cells fixed and stained with oil red O.</p><p><bold>B)</bold> aP2 expression quantitated by real-time qPCR at days 0, 3, 5, and 7 postdifferentiation with results representing the mean &#x000b1; SEM of at least three independent experiments in triplicate.</p><p><bold>C)</bold> Western blotting of Chub-S7 cells at day 4 posttransduction with recombinant adenoviruses confirming comparable levels of total receptor expression. Nondifferentiated, (day 0) nontransduced, cell extracts (ND) are shown for comparison. The positions of PPAR&#x003b3; (open arrow) and non specific band (solid arrowhead) are indicated.</p></caption><graphic xlink:href="nihms-197-0003"/></fig><table-wrap id="T1" position="float"><?landscape?><label>Table 1</label><caption><p>Clinical, biochemical, and body composition details</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Subject (gender)</th><th align="left" valign="middle" rowspan="1" colspan="1">S1 (F)</th><th align="left" valign="middle" rowspan="1" colspan="1">S2 (F)</th><th align="left" valign="middle" rowspan="1" colspan="1">S3 (F)</th><th align="left" valign="middle" rowspan="1" colspan="1">S4 (F)</th><th align="left" valign="middle" rowspan="1" colspan="1">S5 (F)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mutation</td><td align="left" valign="middle" rowspan="1" colspan="1">C114R</td><td align="left" valign="middle" rowspan="1" colspan="1">C131Y</td><td align="left" valign="middle" rowspan="1" colspan="1">C162W</td><td align="left" valign="middle" rowspan="1" colspan="1">FS315X</td><td align="left" valign="middle" rowspan="1" colspan="1">R357X</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (and at presentation, year)</td><td align="left" valign="middle" rowspan="1" colspan="1">41 (34)</td><td align="left" valign="middle" rowspan="1" colspan="1">42 (35)</td><td align="left" valign="middle" rowspan="1" colspan="1">31 (19)</td><td align="left" valign="middle" rowspan="1" colspan="1">13 (8)</td><td align="left" valign="middle" rowspan="1" colspan="1">35 (26)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>) (nonobese &#x0003c; 30)</td><td align="left" valign="middle" rowspan="1" colspan="1">30.0</td><td align="left" valign="middle" rowspan="1" colspan="1">24.2</td><td align="left" valign="middle" rowspan="1" colspan="1">30.5</td><td align="left" valign="middle" rowspan="1" colspan="1">25.9</td><td align="left" valign="middle" rowspan="1" colspan="1">29.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BP (mmHg) (&#x0003c; 130/85)</td><td align="left" valign="middle" rowspan="1" colspan="1">155/95</td><td align="left" valign="middle" rowspan="1" colspan="1">220/120</td><td align="left" valign="middle" rowspan="1" colspan="1">150/100<sup>*</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">125/65</td><td align="left" valign="middle" rowspan="1" colspan="1">125/80<sup>*</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">T2DM/IGT (age at diagnosis, yr) </td><td align="left" valign="middle" rowspan="1" colspan="1">T2DM (41)</td><td align="left" valign="middle" rowspan="1" colspan="1">T2DM (42)</td><td align="left" valign="middle" rowspan="1" colspan="1">IGT (29)</td><td align="left" valign="middle" rowspan="1" colspan="1">T2DM (8)</td><td align="left" valign="middle" rowspan="1" colspan="1">T2DM (26)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PCOS</td><td align="left" valign="middle" rowspan="1" colspan="1">Y</td><td align="left" valign="middle" rowspan="1" colspan="1">Y</td><td align="left" valign="middle" rowspan="1" colspan="1">Y</td><td align="left" valign="middle" rowspan="1" colspan="1">N/A</td><td align="left" valign="middle" rowspan="1" colspan="1">Y</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hepatic steatosis</td><td align="left" valign="middle" rowspan="1" colspan="1">Y</td><td align="left" valign="middle" rowspan="1" colspan="1">Y</td><td align="left" valign="middle" rowspan="1" colspan="1">Y</td><td align="left" valign="middle" rowspan="1" colspan="1">Y</td><td align="left" valign="middle" rowspan="1" colspan="1">Y</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TG (mmol/L) (&#x0003c;1.7)</td><td align="left" valign="middle" rowspan="1" colspan="1">8.9<sup>*</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">4.5</td><td align="left" valign="middle" rowspan="1" colspan="1">5.0<sup>*</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">8.3<sup>*</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">34.8<sup>*</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HDL-C (mmol/L) (&#x0003e;1.29)</td><td align="left" valign="middle" rowspan="1" colspan="1">0.47<sup>*</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">0.89</td><td align="left" valign="middle" rowspan="1" colspan="1">0.71<sup>*</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">0.72<sup>*</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">0.56<sup>*</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FI (pmol/L) (&#x0003c;60)</td><td align="left" valign="middle" rowspan="1" colspan="1">310</td><td align="left" valign="middle" rowspan="1" colspan="1">174</td><td align="left" valign="middle" rowspan="1" colspan="1">220<sup>*</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">475<sup>*</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">170<sup>*</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Predicted total body fat (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">37.4</td><td align="left" valign="middle" rowspan="1" colspan="1">28.8</td><td align="left" valign="middle" rowspan="1" colspan="1">38.1</td><td align="left" valign="middle" rowspan="1" colspan="1">31.3</td><td align="left" valign="middle" rowspan="1" colspan="1">36.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Measured total body fat (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">26 <sup>-0.8</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">23 <sup>-1.2</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" rowspan="1" colspan="1">26 <sup>nd</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">21 <sup>-1.1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Measured lower limb fat (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">20</td><td align="left" valign="middle" rowspan="1" colspan="1">17</td><td align="left" valign="middle" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" rowspan="1" colspan="1">21</td><td align="left" valign="middle" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Measured truncal fat (%)</td><td align="left" valign="middle" rowspan="1" colspan="1">30</td><td align="left" valign="middle" rowspan="1" colspan="1">27</td><td align="left" valign="middle" rowspan="1" colspan="1">nd</td><td align="left" valign="middle" rowspan="1" colspan="1">31</td><td align="left" valign="middle" rowspan="1" colspan="1">28</td></tr></tbody></table><table-wrap-foot><p>BMI, body mass index; BP, blood pressure; T2DM, type 2 diabetes mellitus; IGT, impaired glucose tolerance; PCOS, polycystic ovarian syndrome; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; FI, fasting insulin; Predicted total body fat was calculated as follows (<xref ref-type="bibr" rid="R12">Black et al., 1983</xref>): males % fat = (1.281 &#x000d7; BMI) - 10.13: females % fat = (1.48 &#x000d7; BMI) - 7.00; measured total and depot-specific body fat were determined using dual-energy X-ray absorptiometry, with corresponding z scores for total body fat shown as superscript; Hepatic steatosis was diagnosed according to standard radiological criteria; F, female; healthy adult values where available are shown in parentheses; asterisk denotes patient studied on treatment; N/A, not applicable; nd, not determined.</p></table-wrap-foot></table-wrap></sec></back></article> 